Member Info for daveycaferacer

just been Bid 80p to sell, not that I am going to, but interesting to see the price the book is now running at

550,000 in the first 2 hours of trading, (average is 1m per day) so looks like this will be a very big day today

HK based Zeal Asset Management Ltd,has filed Form 13F for Q1 2020.Opened NEW positions in $HCM & $ZLAB

Nice to see another new Institution opening a position

I agree Taff, £1 on its way I suspect ;o-)

$4.01 divided by 5 = 80 cents
80 divided by 1.23 USD to GBP = 65
65p equivalent

This is not U.S. listed, it is London listed with an American Depository Receipt on NASDAQ

NASDAQ in pre-market is 65p equivalent

Laura Fonda is just the admin person who submitted the form, she is not the owner of the shares

it is up 1% in the last year

er I know ;o-)

I doubt they are that intelligent, the order book is fairly automated, sellers sell into each rise which is why the price doesn't continually climb at the moment. If we had more buys than sells the price would rise.

I've never seen the spread this narrow on #Tils

I'm lucky, as I've been an Investor for over 10 years so have already realised significant returns, but also add to my holding regularly. I am still of the view this is another Incyte or Genmab in the making.

The dataset is being evaluated against data from 2400 patients but that that is all

StemPrintER™ is pre-clinical, it is not even at Stage 1 trial yet, pre-clinical meaning it is currently being tested in animals, not humans.

StemPrintER™ is a multi-gene signature diagnositic assay intended for early diagnosis of estrogren receptor positive ER+/HER2 negative breast cancer patients, based on the detection of cancer stem cell markers. The assay has been evaluated in an initial retrospective validation study using a consecutive cohort of approximately 2400 patients with breast cancer.

yes, it does seem the anti Chimna sentiment is having an impact (again). The market is not putting a valuation on the Company anywhere near sensible DCF measures at the moment. When the Company becomes very profitable in 2023 or 2024 the market may wake up. I think a HK listing would help address the anti-China issue too but the Company clearly has good reasons not to pursue that at the moment.

yes, but I was speaking literally. ASCO does not provide regulatory approval for anything.

sorry to disappoint but ASCO do not approve anything, the FDA provides Regulatory approval, the American Society of Clinical Oncology's meetings are an important and influential setting however

The Company is to participate in a virtual fireside chat at the Bank of America 2020 Health Care Conference on Thursday, May 14, 2020 9:40 a.m. Eastern Daylight Time (EDT).

The discussion will be webcast live and can be accessed at www.chi-med.com in the Shareholder Information section under “Events, Circulars & Forms.” Investors interested in listening to the live webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter for approximately 90 days.

Members of the senior management team will also attend virtual one-on-one meetings at the Bank of America Health Care Conference on May 14, as well as during the following other conferences:

https://newsfilter.io/a/95688308c0b36a267567f0a443376944

very sensible decision to suspend the dividend

American specialist Biotech Investors take a lot of interest in ASCO, especially smaller Biotechs with potential best or first-in-class assets